Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2, and c-Fos at the nuclear envelope

José María González,1 Ana Navarro-Puche,1 Berta Casar,2 Piero Crespo,2 and Vicente Andrés1

1Laboratory of Vascular Biology, Department of Molecular and Cellular Pathology and Therapy, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas (CSIC), 46010 Valencia, Spain
2Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC-IDICAN-Universidad de Cantabria, Department of Molecular Biology, Faculty of Medicine, 39001 Santander, Spain

S equestration of c-Fos at the nuclear envelope (NE) through interaction with A-type lamins suppresses AP-1–dependent transcription. We show here that c-Fos accumulation within the extraction-resistant nuclear fraction (ERNF) and its interaction with lamin A are reduced and enhanced by gain-of and loss-of ERK1/2 activity, respectively. Moreover, hindering ERK1/2-dependent phosphorylation of c-Fos attenuates its release from the ERNF induced by serum and promotes its interaction with lamin A. Accordingly, serum stimulation rapidly releases preexisting c-Fos from the NE via ERK1/2-dependent phosphorylation, leading to a fast activation of AP-1 before de novo c-Fos synthesis. Moreover, lamin A–null cells exhibit increased AP-1 activity and reduced levels of c-Fos phosphorylation. We also find that active ERK1/2 interacts with lamin A and co-localizes with c-Fos and A-type lamins at the NE. Thus, NE-bound ERK1/2 functions as a molecular switch for rapid mitogen-dependent AP-1 activation through phosphorylation-induced release of preexisting c-Fos from its inhibitory interaction with lamin A/C.

Introduction

c-Fos is a member of the dimeric activator protein 1 (AP-1) transcription factor family that regulates key cellular processes, including cell proliferation, death, survival differentiation, and oncogenetic transformation (Shaulian and Karin, 2002; Eferl and Wagner, 2003). c-fos is an “early response” gene that undergoes rapid transcriptional activation in response to multiple pathophysiological stimuli (e.g., growth factors, chemical and physical stress, etc.) (Shaulian and Karin, 2002). Fine regulation of c-Fos activity is achieved via its interaction with regulatory proteins that can either enhance or inhibit AP-1 activity, and through posttranslational processing of preexisting or newly synthesized c-Fos protein (Piechaczyk and Blanchard, 1994; Shaulian and Karin, 2002). For example, c-Fos can be phosphorylated by protein kinases C and A, cdc2 (Abate et al., 1991), FRK (Deng and Karin, 1994), extracellular signal-regulated kinase 7 (ERK7) (Abe et al., 1999), and the mitogen-activated protein kinases (MAPK) ERK1/2 (Monje et al., 2003) and p38 (Tanos et al., 2005). Importantly, c-Fos transcriptional activity is modulated through reversible phosphorylation by some of these kinases, including ERK1/2 (Hunter and Karin, 1992; Hill and Treisman, 1995; Monje et al., 2003). Phosphorylation of c-Fos by ERK1 and RSK occurs soon after serum stimulation (Chen et al., 1993, 1996). Moreover, a docking site for ERK in c-Fos facilitates its sequential phosphorylation in multiple C-terminal sites upon prolonged ERK activation (Murphy et al., 2002). The binding of growth factors, differentiation stimuli, and cytokines to cell surface receptors promotes the activation of the small GTPase Ras and dual phosphorylation (activation) of ERKs. Active ERK1 and ERK2 translocate into the nucleus, where they phosphorylate several transcriptional regulators (e.g., c-Fos) that cause a rapid induction of immediate early genes (Sharrocks, 2001).

© 2008 González et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
c-Fos accumulation at the extraction-resistant nuclear fraction is regulated by lamin A/C expression and the level of c-Fos phosphorylation

We first examined by Western blot the consequences of altering lamin A/C expression on the amount of c-Fos within the soluble nuclear fraction (SNF) and extraction-resistant nuclear fraction (ERNF) of cultured cells. Lamin A/C–null mouse embryonic fibroblasts (MEFs) exhibited decreased ERNF-associated and increased SNF-associated level of c-Fos compared with wild-type controls (Fig. 1A), and ectopically expressed CFP-Lamin A increased the presence of both endogenous c-Fos and recombinant YFP–c-Fos within the ERNF of HEK293 and COS7 cells, respectively (Fig. 1B). Consistent with our previous confocal microscopy studies in MEFs (Ivorra et al., 2006), CFP-lamin A overexpression in NIH-3T3 and COS7 cells recruited YFP–c-Fos

Results

c-Fos accumulation at the extraction-resistant nuclear fraction is regulated by lamin A/C expression and the level of c-Fos phosphorylation

In addition to fulfilling structural functions at the nuclear envelope (NE), A-type lamins (lamin A and C) play important roles in the control of gene expression via their interaction with histones, transcription factors (e.g., SREBP1, MOK2, BAF, GCL, Mel18, and c-Fos), and cell cycle regulators (e.g., the retinoblastoma protein [pRb] and cyclin D3) (Taniura et al., 1995; Gruenbaum et al., 2005; Mariappan and Parnaik, 2005; Broers et al., 2006; Heessen and Fornerod, 2007; Vlcek and Foisner, 2007). We have recently shown that lamin A/C–dependent sequestration of c-Fos at the NE reduces AP-1 DNA-binding activity and cellular proliferation (Ivorra et al., 2006). However, the molecular mechanisms controlling this interaction remain unknown. Here we tested the hypothesis that ERK1/2 is a critical regulator of the interaction between lamin A/C and c-Fos. We show that active ERK1/2 directly interacts with lamin A and colocalizes with c-Fos at the NE. Therein, mitogen-induced ERK1/2-mediated phosphorylation of c-Fos releases it from the inhibitory interaction with lamin A/C before de novo synthesis of c-Fos, thus allowing a rapid induction of AP-1 activity.
Compared with serum-starved cells, the level of c-Fos protein was up-regulated in cultures stimulated for 90 min, which was markedly reduced after 180 min of serum stimulation (Fig. 1E, lanes 1–3). Moreover, treatment with the proteasome inhibitor MG132 abrogated c-Fos down-regulation at 180 min after serum stimulation (Fig. 1E, lane 5 vs. 3). These findings are in agreement with the concept that mitogen stimulation leads to de novo c-Fos expression, which then undergoes proteasome-dependent degradation (Bossis et al., 2003; Ito et al., 2005). In line with previous studies (Monje et al., 2003), we found that preincubation of serum-starved cells with the ERK1/2 inhibitor U0126 greatly reduces c-Fos level in cells stimulated with serum for 90 min (Fig. 1F). Therefore, to circumvent the possible influence of ERK1/2 inhibitors on c-Fos synthesis and/or degradation, the effects of U0126 and PD98059 on c-Fos expression and subnuclear localization was investigated using the protocol schematized in Fig. 2A. In brief, mitogen-depleted cells were stimulated with serum for 150 min in the presence of MG132 (25 μM) to prevent c-Fos degradation. After c-Fos induction (~90 min), protein synthesis was inhibited with cycloheximide (10 μg/ml). When indicated, the ERK1/2 inhibitors PD98059 (20 μM) and U0126 (10 μM) were added for the last 50 min (B) Western blot analysis of the SNF and ERNF of NIH-3T3 cells treated as described above. Numbers on the side of the blots indicate molecular weight (in kD). Arrows point to c-Fos species with different degree of phosphorylation.

We next sought to investigate the molecular mechanisms regulating the association of c-Fos with the NE. Although two main species of c-Fos with different electrophoretic mobilities were detected in the SNF of NIH-3T3 cells restimulated with serum after a period of starvation, the faster migrating band predominated in the ERNF (Fig. 1C). Incubation of the SNF with alkaline phosphatase increased c-Fos mobility (Fig. 1D, lane 1 vs. 2), but this change was not seen in the presence of phosphatase and protease inhibitors (Fig. 1D, lanes 3 and 4). Thus, the SNF of serum-stimulated cells accumulates hyperphosphorylated and hypophosphorylated c-Fos, whereas the ERNF predominantly accumulates the hypophosphorylated form of c-Fos. These results suggested that mitogen-dependent phosphorylation of c-Fos facilitates its release from the NE.

We then focused our attention on ERK1/2-dependent signaling, the main transduction pathway implicated in the rapid and transient phosphorylation and subsequent activation of c-Fos elicited by mitogens (Monje et al. 2003). As expected, Western blot analysis of the SNF of NIH-3T3 cells revealed the activation (phosphorylation) of ERK1/2 after serum stimulation (Fig. 1E). Compared with serum-starved cells, the level of c-Fos protein was up-regulated in cultures stimulated for 90 min, which was markedly reduced after 180 min of serum stimulation (Fig. 1E, lanes 1–3). Moreover, treatment with the proteasome inhibitor MG132 abrogated c-Fos down-regulation at 180 min after serum stimulation (Fig. 1E, lane 5 vs. 3). These findings are in agreement with the concept that mitogen stimulation leads to de novo c-Fos expression, which then undergoes proteasome-dependent degradation (Bossis et al., 2003; Ito et al., 2005). In line with previous studies (Monje et al., 2003), we found that preincubation of serum-starved cells with the ERK1/2 inhibitor U0126 greatly reduces c-Fos level in cells stimulated with serum for 90 min (Fig. 1F). Therefore, to circumvent the possible influence of ERK1/2 inhibitors on c-Fos synthesis and/or degradation, the effects of U0126 and PD98059 on c-Fos expression and subnuclear localization was investigated using the protocol schematized in Fig. 2A. In brief, mitogen-depleted cells were stimulated with serum for 150 min in the presence of MG132 to avoid proteasome-dependent degradation of c-Fos. To prevent further protein synthesis after reaching a high level of c-Fos expression, cycloheximide was added at 90 min. Finally, U0126 or PD98059 was added at 100 min after serum stimulation. In agreement with the results of Fig. 1C, the ERNF and SNF of NIH-3T3 cells
c-Fos or YFP (as negative control). Fig. 3, A–C show representative images and intensity line profiles. In agreement with our previous FRET studies (Ivorra et al., 2006), cells cotransfected with CFP-lamin A/YFP–c-Fos exhibited a significant increase in FRET efficiency in the perinuclear rim compared with negative controls (Fig. 3 D). Addition of U0126 inhibited ERK1/2, as revealed by reduced ERK1/2 phosphorylation in the SNF (Fig. 3 E), and significantly increased FRET efficiency in cells cotransfected with CFP-lamin A/YFP but not with CFP-lamin A/YFP (Fig. 3 D). These results indicated that ERK1/2 inhibition increases the level of c-Fos/lamin A interaction in vivo.

Constitutive ERK1/2 activation reduces the presence of c-Fos in the ERNF

Consistent with the results of Fig. 2 B, treatment of U2OS cells with U0126 reduced the amount of hyperphosphorylated c-Fos in the SNF and ERNF fractions, and increased the amount of hypophosphorylated c-Fos within the ERNF (Fig. 4 A, lane 1 vs. 2). Overexpression of MEKE, a constitutively active form of MEK1, markedly augmented ERK1/2 phosphorylation in the SNF compared with controls transfected with empty vector (Fig. 4 A, pERK1/2, lane 2 vs. 3). This effect coincided with diminished retention of c-Fos in the ERNF, especially of the hyperphosphorylated species, which appeared to accumulate in the SNF (Fig. 4 A, lane 2 vs. 3). Thus, constitutive activation of ERK1/2 reduces the amount of ERNF-associated c-Fos.

ERK1/2 inhibition increases the interaction of c-Fos with lamin A in vivo

We next performed fluorescence resonance energy transfer (FRET) confocal microscopy studies to examine the in vivo interaction between c-Fos and lamin A. FRET efficiency determined as the increment in CFP fluorescence after YFP photobleaching (Kenworthy, 2001) was quantified in asynchronously growing COS7 cells cotransfected with CFP-lamin A and either YFP–c-Fos or YFP (as negative control). Fig. 3, A–C show representative images and intensity line profiles. In agreement with our previous FRET studies (Ivorra et al., 2006), cells cotransfected with CFP-lamin A/YFP–c-Fos exhibited a significant increase in FRET efficiency in the perinuclear rim compared with negative controls (Fig. 3 D). Addition of U0126 inhibited ERK1/2, as revealed by reduced ERK1/2 phosphorylation in the SNF (Fig. 3 E), and significantly increased FRET efficiency in cells cotransfected with CFP-lamin A/YFP but not with CFP-lamin A/YFP (Fig. 3 D). These results indicated that ERK1/2 inhibition increases the level of c-Fos/lamin A interaction in vivo.

ERK1/2 inhibition increases the interaction between c-Fos and lamin A in vivo

Figure 3. ERK1/2 inhibition increases the interaction between c-Fos and lamin A in vivo. FRET was measured in NIH-3T3 cells using the acceptor photobleaching method. Cells were transiently cotransfected with CFP-lamin A and either YFP (negative control) or YFP–c-Fos. Transfected cells were maintained in 10% NBS for 24 h and U0126 was added for the last 50 min when indicated. (A) Representative images of one YFP–c-Fos/CFP-lamin A–transfected U0126-treated cell before and after YFP photobleaching. The two perinuclear regions marked with white squares enlarged in B illustrate increased CFP fluorescence after photobleaching. (C) Fluorescence line profile analysis of CFP-lamin A intensity throughout the entire perinuclear rim shown in A before (green) and after (red) photobleaching of YFP. (D) Quantification of protein–protein interactions calculated as the percentage of CFP fluorescence increment after photobleaching in 20–30 cells from three independent experiments. (E) Western blot analysis of the SNF of cells maintained in 10% NBS treated or not with U0126. Numbers on the side of the blots indicate molecular weight (in kD).

Manipulated as described above predominantly contained the fastest migrating hypophosphorylated and the two migrating forms of c-Fos, respectively (Fig. 2 B, ERNF: lanes 1 and 3; SNF: lanes 5 and 7). Treatment with either PD98059 or U0126 inhibited ERK1/2 activation, as revealed by the reduced amount of phosphorylated ERK1/2 (pERK1/2) in the SNF (Fig. 2 B, PD98059: lane 5 vs. 6; U0126: lane 7 vs. 8), and caused the accumulation of hypophosphorylated c-Fos both in the ERNF (Fig. 2 B, PD98059: lane 1 vs. 2; U0126: lane 3 vs. 4) and SNF (Fig. 2 B, PD98059: lane 5 vs. 6; U0126: lane 7 vs. 8). The pattern of expression of Sp1 and nucleoporin-50 + Npap60 (NUP50) suggested the absence of cross-contamination in these studies (Fig. 2 B). The results presented thus far indicated that the amount of c-Fos in the ERNF and perinuclear rim is regulated by the level of lamin A/C expression. They also suggested that inhibition of ERK1/2 activity reduces the extent of c-Fos phosphorylation and promotes its accumulation within the ERNF.
ERK1/2 activation is a physiological mechanism for releasing c-Fos from the ERNF.

Mutations that hinder ERK1/2-dependent phosphorylation of c-Fos impair its release from the ERNF and enhance its interaction with lamin A.

We next sought to assess whether physiological levels of ERK1/2 activation can release c-Fos from the ERNF. To this end, we investigated in U2OS cells the subnuclear localization of ectopically expressed wild-type c-Fos (c-Fos-wt) and c-Fos-m, a mutant in which four residues that undergo ERK1/2-dependent phosphorylation are rendered unphosphorylatable (T232A, T325A, T331A, S374A) (Monje et al., 2003) (see scheme in Fig. 4 B). The level of serum-dependent ERK1/2 activation was similar in cells transfected with c-Fos-wt and c-Fos-m, as revealed by comparable increases in the amount of pERK1/2 in the SNF (Fig. 4 B, c-Fos-wt: lane 2 vs. 3; c-Fos-m: lane 4 vs. 5). Serum-inducible ERK1/2 activation coincided with reduced amount of ERNF-associated c-Fos-wt (Fig. 4 B, lane 2 vs. 3), but this effect was weaker for c-Fos-m (Fig. 4 B, lane 4 vs. 5). The mobility shift of mutated c-Fos-m upon stimulation is likely due to ERK1/2-dependent phosphorylation at site(s) that is(are) not important for lamin A/C association and possibly for c-Fos activation, per se (e.g., S21, S32, S70, S133; see scheme in Fig. 4 B). These findings suggested that serum-inducible phosphorylation of c-Fos through ERK1/2 activation is a physiological mechanism for releasing c-Fos from the ERNF.

To directly examine whether ERK1/2-dependent phosphorylation of c-Fos affects its affinity for lamin A, we performed in vitro pull-down assays using a GST-lamin A fusion protein containing amino acids 37–244 of rat lamin A, which interacts with recombinant c-Fos (Ivorra et al., 2006). GST-lamin A specifically interacted with the endogenous c-Fos protein present in extracts from serum-stimulated NIH-3T3 cells (Fig. 5 A, lane 3 vs. 4). Moreover, the amount of GST-lamin A–bound c-Fos was greatly increased upon treatment of cells with PD98059 (Fig. 5 B, lane 3 vs. 4). We also compared the binding of GST-lamin A to c-Fos-wt and c-Fos-m, which were ectopically expressed in serum-stimulated U2OS cells. Examination of input samples suggested the presence of phosphorylation activity in these cultures because c-Fos-wt exhibited slower electrophoretic mobility than c-Fos-m (Fig. 5 C, lane 2 vs. 3). Moreover, GST-lamin A specifically interacted with the endogenous c-Fos protein present in extracts from serum-stimulated NIH-3T3 cells (Fig. 5 A, lane 3 vs. 4). Moreover, the amount of GST-lamin A–bound c-Fos was greatly increased upon treatment of cells with PD98059 (Fig. 5 B, lane 3 vs. 4). We also compared the binding of GST-lamin A to c-Fos-wt and c-Fos-m, which were ectopically expressed in serum-stimulated U2OS cells. Examination of input samples suggested the presence of phosphorylation activity in these cultures because c-Fos-wt exhibited slower electrophoretic mobility than c-Fos-m (Fig. 5 C, lane 2 vs. 3). Moreover, GST-lamin A specifically interacted with the endogenous c-Fos protein present in extracts from serum-stimulated NIH-3T3 cells (Fig. 5 A, lane 3 vs. 4). Moreover, the amount of GST-lamin A–bound c-Fos was greatly increased upon treatment of cells with PD98059 (Fig. 5 B, lane 3 vs. 4). We also compared the binding of GST-lamin A to c-Fos-wt and c-Fos-m, which were ectopically expressed in serum-stimulated U2OS cells. Examination of input samples suggested the presence of phosphorylation activity in these cultures because c-Fos-wt exhibited slower electrophoretic mobility than c-Fos-m (Fig. 5 C, lane 2 vs. 3).
increase in AP-1 DNA-binding activity in the SNF (Fig. 6 D, lanes 2 vs. 3), which was not affected by inhibiting de novo protein synthesis (lanes 4 vs. 5) but was blunted upon pharmacological inhibition of ERK1/2 (lanes 6 vs. 7). AP-1 DNA-binding activity was further increased after 90 min of serum stimulation (Fig. 6 D, lane 8) through a mechanism requiring both de novo protein synthesis (lane 9) and ERK1/2 activation (lane 10). Sp1 DNA-binding activity remained essentially unaffected by all the above manipulations (Fig. 6 E).

Lamin A/C inhibits AP-1 activity and facilitates c-Fos phosphorylation

We have previously shown that lamin A/C overexpression suppresses AP-1 DNA binding and transcriptional activity (Ivorra et al., 2006). To gain further insight into the role of A-type lamins on AP-1 function, we compared the kinetics of AP-1 DNA binding and transcriptional activity in wild-type versus lamin A/C–null MEFs. Consistent with the results in NIH-3T3 cells (Fig. 6 D), EMSAs demonstrated a progressive increase in AP-1 DNA-binding activity in wild-type MEFs stimulated with serum for 15 and 90 min (Fig. 7 A). Compared with wild-type controls, two dramatic alterations in AP-1 DNA-binding activity

Serum-dependent activation of ERK1/2 rapidly releases preexisting c-Fos from the ERNF and induces AP-1 DNA-binding activity

The results presented thus far suggested that serum-inducible ERK1/2-dependent phosphorylation of c-Fos releases is from the inhibitory interaction with A-type lamins. To assess whether this process might be physiologically relevant, we investigated the effects of serum stimulation on the subnuclear localization of endogenous c-Fos and on AP-1 DNA-binding activity. In agreement with numerous studies, Western blot analysis of NIH-3T3 whole cell extracts demonstrated the activation of pERK1/2 and up-regulation of c-Fos after 15 and 60 min of serum stimulation, respectively (Fig. 6 A). Coinciding with the peak of ERK1/2, c-Fos expression diminished in the ERNF and accumulated within the SNF (Fig. 6 B). The presence of c-Fos in the NE and its release after 15 min of serum stimulation was also observed in double immunofluorescence confocal microscopy experiments with U2OS cells submitted to in situ extraction of soluble cytoplasmic and nucleoplasmic proteins (Fig. 6 C). Moreover, electrophoretic mobility shift assays (EMSA) revealed that 15 min of serum induction causes in NIH-3T3 cells a rapid
Figure 6. Serum-inducible ERK1/2 activation correlates with the release of preexisting c-Fos from the ERNF and causes a rapid induction of AP-1 DNA-binding activity. (A and B) NIH-3T3 cells were starved for 24 h and stimulated with 10% NBS for the indicated times. Whole cell extracts (A), or SNF and ERNF (B) were analyzed by Western blot. Of note, the amount of protein analyzed in the blots of B was ~14 times higher than in A. Numbers on the side of the blots indicate molecular weight (in kD). (C) Double immunofluorescence of c-Fos and lamin A/C in U2OS cells. Top images: Asynchronously growing control cells. Middle and bottom images: Starved and serum-stimulated cells in situ extracted and treated with DNase. Images in the right column show 3D representation of c-Fos signal intensity in lamin A/C-containing perinuclear rim. Graph shows the total intensity of c-Fos signal per total lamin A/C-containing perinuclear area of in situ extracted cells (n = 30 cells of each condition). (D and E) NIH 3T3 were starved for 24 h and stimulated with 10% NBS for the indicated times. When indicated, cycloheximide (CHX, 10 μg/ml) or U0126 (10 μM) was added 1 h before serum stimulation. EMSA was performed using 10 fmol of a consensus AP-1 (D) or Sp1 (E) radiolabeled probe and SNF (5 μg total protein). The graphs show the quantification of DNA-binding activity as assessed by densitometric analysis. Reactions in lanes 11 and 22 contained a 50-fold molar excess of competitor (unlabeled AP-1 or Sp1 consensus oligonucleotide, respectively).
were observed in lamin A/C–null MEFs: a marked induction under serum starvation, and a lack of activation at 15 min of serum restimulation; in contrast, Sp1 DNA-binding activity remained largely unaffected upon lamin A/C ablation (Fig. 7 A). As shown in Fig. 7 B, lamin A/C–null MEFs exhibited significantly higher AP-1-dependent transcriptional activity, as revealed in transient transfection assays with the AP-1–responsive coll73-luciferase reporter gene. Silencing lamin A/C expression with miRNA also increased activity of coll73-luciferase in U2OS cells (Fig. 7 C). Moreover, we found that both the maximum level of c-Fos protein and the relative abundance of its hyperphosphorylated form were reduced in serum-stimulated lamin A/C compared with wild-type MEFs (Fig. 7 D).

**ERK1/2 interacts with lamin A in vitro and in vivo**

We next performed immunoprecipitation-coupled Western blot analysis to test whether ERK1/2 could directly interact with lamin A/C. Anti-lamin A serum, but not preimmune serum, co-precipitated lamin A and ERK1/2 (Fig. 8 A). Of note, the anti-lamin A serum precipitated phosphorylated ERK1/2 (Fig. 8 A), suggesting that active ERK1/2 can interact with lamin A/C in vivo. In contrast, lamin A and the transcription factor Sp1 did not co-precipitate, whereas Sp1-ERK2 complexes could be immunoprecipitated with either anti-Sp1 or anti-ERK2 antibodies, in agreement with previous studies (Milanini-Mongiat et al., 2002).

GST pull-down assays revealed that amino acids 247 – 355 of lamin A/C, but not the fragments spanning amino acids 37 – 244 and 356 – 571, associated to ERK1/2 from HEK293 cells (Fig. 8 C). We extended these studies by determining the region in ERK2 responsible for binding to lamin A/C. In particular, we tested two interaction “hot spots”: the CD domain and the Insert region (Robinson et al., 1998). We found that mutations D316,319A that abrogate interactions mediated through the CD domain (Tanoue et al., 2000) did not affect the binding of ERK2 to lamin A/C. Conversely, an ERK2 Insert region deletion mutant (Δ241-272) (Whitehurst et al., 2004) and point mutants within this region, Y261N and S264Y, were impaired in their association with lamin A/C (Fig. 8 D).
We recently reported that sequestration of c-Fos at the NE through its interaction with A-type lamins is a mechanism of suppressing AP-1–dependent transcription in mammalian cells (Ivorra et al., 2006). In the present study we provide evidence that disruption of lamin A/C (sc-20680) antibodies as indicated. (C) GST-lamin A fusion proteins containing amino acid residues 37-244, 243-388 or 453-571 of rat lamin A were tested for their interaction with endogenous ERK1/2 from whole HEK293 cell extracts. Approximately 90% of the reaction mixture was precipitated with glutathione-Sepharose 4B, washed and analyzed by Western blot. (D) Lysates from HEK293 cells overexpressing FLAG-tagged ERK2 (wild-type and several mutants) were immunoprecipitated with an anti-FLAG antibody. Both the input and the whole immunoprecipitated material were subjected to Western blot analysis using anti-FLAG and anti-lamin A/C (sc-20680) antibodies. In the scheme in C and D, (+) and (−) indicate positive and negative interactions, respectively. NLS: Nuclear localization signal. Numbers on the side of the blots indicate molecular weights (in kD).
after stimulation (Kruijer et al., 1984; Kerr et al., 1988; Monje et al., 2003; Ivorra et al., 2006; Murphy and Blenis, 2006). In line with this notion, we observed maximum c-Fos protein expression at 60–90 min after serum stimulation (Fig. 1E, Fig. 6A), coinciding with a peak of AP-1 DNA-binding activity that could be attenuated by inhibitors of either protein synthesis or ERK1/2 activity (Fig. 6D). Our novel observation is the induction of AP-1 DNA-binding activity as early as 15 min after serum addition concomitantly with maximum ERK1/2 activity and the release of c-Fos from the ERNF to the nucleoplasm in a manner dependent on ERK1/2 activation but independent of de novo facilitation.

It is generally accepted that mitogen-dependent activation of ERK1/2 in fibroblasts is a biphasic process consisting of a rapid and strong burst of kinase activity peaking at 5–15 min, followed by a second wave of lower activity that persists throughout the G1 phase of the cell cycle (Kahan et al., 1992; Meloche et al., 1992; Meloche, 1995). c-Fos is expressed minimally in most nongrowing cells as well as during the initial phase of mitogen-induced ERK activation, with a peak of de novo c-Fos protein synthesis and AP-1 activation occurring between 1–2 h after stimulation (Kruijer et al., 1984; Kerr et al., 1988; Monje et al., 2003; Ivorra et al., 2006; Murphy and Blenis, 2006). In line with this notion, we observed maximum c-Fos protein expression at 60–90 min after serum stimulation (Fig. 1E, Fig. 6A), coinciding with a peak of AP-1 DNA-binding activity that could be attenuated by inhibitors of either protein synthesis or ERK1/2 activity (Fig. 6D). Our novel observation is the induction of AP-1 DNA-binding activity as early as 15 min after serum addition concomitantly with maximum ERK1/2 activity and the release of c-Fos from the ERNF to the nucleoplasm in a manner dependent on ERK1/2 activation but independent of de novo...
from the interaction with A-type lamins (see above). Indeed, AP-1-dependent DNA-binding and transcriptional activity were significantly higher in lamin A/C-null versus wild-type MEFs and in U2OS cells in which lamin A/C expression was silenced with miRNA (Fig. 7, A–C). Our results also suggest that the efficiency of serum-inducible activation (phosphorylation) of the small preinduction levels of c-Fos elicited by ERK1/2 is aided by their colocalization at the NE (Fig. 7 D). We are currently investigating whether ERK1/2–lamin A/C complex formation may help prolong the activation state of ERK1/2 by maintaining these signal transducers in a reservoir out of the reach of soluble nuclear phosphatases. It will be also of interest to examine whether A-type lamins serve a scaffolding function only for ERK1/2-dependent activation of c-Fos, or whether induction of other transcription factors also requires the activity of NE-associated signal transducers.

The Insert and the CD domains of ERK1/2 are involved in protein–protein interactions. ERK1/2 substrate docking can be selectively dissociated in vitro by single point mutations without perturbing ERK activation or its intrinsic catalytic activity (Dimitri et al., 2005). Indeed, mutations affecting the Insert region ({H9004}241–272, Y261N, and S264P) or the CD domain (D316,319A) alter the interaction of ERK2 with some substrates (Tanoue et al., 2000; Whitehurst et al., 2004; Casar et al., 2007). We have shown here that the ERK2–lamin A/C interaction requires the Insert domain of ERK2 and the coil 2 of lamin A/C. Other proteins such as PEA15 (Whitehurst et al., 2004) and Mxi2 (Casar et al., 2007) also interact with ERK through the Insert region. The determinant mediating in this interaction is a “reverse D domain”, with a consensus sequence R/K/H-X_a-H_b (where H are Leu, Ile, or Val) (Callaway et al., 2005). Notably, the R/K/H-X_a-H_b motif is present in the region of A-type lamins, which we found to intervene in their interaction with ERK1/2 (RIRISL at residues 296–301).

Figure 10. Model for the rapid activation of AP1 upon mitogen stimulation. In serum-deprived cells, the c-Fos protein is expressed at low level predominantly in a hypophosphorylated state and associated to the NE through its interaction with A-type lamins. Under these conditions, transcription of AP-1 target genes is off. Upon mitogen stimulation, phosphorylated (active) ERK1/2 bound to lamin A/C phosphorylates c-Fos, causing its release from the NE. Hyperphosphorylated nucleoplasmic c-Fos can then heterodimerize with AP-1 family members (e.g., cJun), thus allowing the transcriptional activation of AP-1–responsive genes before de novo c-Fos synthesis.
In this study, we have focused our attention on how mitogenic signals regulate the interaction between c-Fos and lamin A/C. Further research is required to assess whether additional pathophysiological conditions regulate this interaction and the underlying molecular mechanisms. Of notable interest in this regard are the inherited diseases termed laminopathies, which are caused by either mutations in the LMNA gene (which encodes for A-type lamins) or defective posttranslational processing of prelamin A (Worman and Bonne, 2007). Notably, lamin A/C and lamin-associated polypeptides can physically interact with histones, chromatin, and transcription factors (e.g., c-Fos, SREBP1, MOK2, BAF, GCL, Mel18), suggesting that altered gene expression contributes to the pathogenesis of laminopathies (Taniura et al., 1995; Grunbaum et al., 2005; Broers et al., 2006; Heessen and Fornerod, 2007; Vlcek and Foisner, 2007). Indeed, microarray studies using fibroblasts from Hutchinson-Gilford progeria syndrome patients revealed differential transcription factor expression (Ly et al., 2000; Csoka et al., 2004). Moreover, certain pathogenic lamin A mutations cause alterations in the transcription factors MOK2 (Dreuillet et al., 2008) and SREBP1 (Lloyd et al., 2002; Hubner et al., 2006). Interestingly, transgenic mice overexpressing either wild-type MEK5 or constitutively active MEK1 exhibit excessive ERK1/2-dependent signaling and dilated cardiomyopathy (Bueno et al., 2000; Nicol et al., 2001), a clinical manifestation of several laminopathies. Moreover, expression of the Emery-Dreifuss muscular dystrophy—causing H222P–lamin A mutant protein in homozygous lmnaH222PH222P knock-in mice causes in the heart aberrant ERK1/2 activity and myopathy, and leads to activation of several MAPKs—including ERK1/2—and downstream target genes in cultured cells (Muchir et al., 2007). It is also noteworthy that MEK/ERK pathway inhibition improves defective myogenic factor expression and differentiation of C2C12 myoblasts expressing the Emery-Dreifuss muscular dystrophy—causing R453W–lamin A mutant (Favreau et al., 2004, 2008). In the light of the aforementioned studies and the findings reported herein, it will be of interest to assess whether pathogenic lamin A/C mutants alter the interaction of c-Fos and/or ERK1/2 at the NE, and if so, whether they affect the regulation and function of AP-1 target genes.

Materials and methods

**Antibodies**

Primary antibodies directed against c-Fos (sc-52), lamin A/C (sc-7292 in Fig. 1 B, A, and 6 C, 7 C, and 9; sc-7293 in Figs. 1 A, C, F, 2, 5, 6 A and B, and 7 D; and sc-20680 in Fig. 8), lamin B (sc-6217), GST (sc-138), ERK2 (sc-154 and sc-1647 only in Fig. 9 D), pERK1/2 (sc-7383), Sp1 (sc-59-G), α-tubulin (sc-8035), anti-FLAG, and HRP-coupled secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. Anti-NUP50 and anti-GFP were from Abcam (ab4005) and Invitrogen (A6455), respectively.

**Plasmids**

pECFP-YFP was constructed by inserting YFP into pECFP-C1 (gift from J. López-Giménez, University of Glasgow, Scotland). The following plasmids are described elsewhere: pGEX-lamin A (37–244), pGEX-lamin A (247–355), and pGEX-lamin A (356–571) (gift from T. Ozaki, Chiba Cancer Center Research Institute, Japan) (Ozaki et al., 1994); pEYFP-Fos and pECFP-lamin A (Ivorra et al., 2006); pmycCMVERK2-MEK1 (Robinson et al., 1998); pCDNAHA-ERK2 (Crespo et al., 1994); pCEFL-MEKE (Sanz-Moreno et al., 2003); pCMVFLAG-ERK2; pCMVFLAG-ERK2-Y261N; pCMVFLAG-ERK2-
Δ241-272; pCMVFLAG-ERK2S264P and pCMVFLAG-ERK2-D316A-D319A (Robinson et al., 2002); pCEFL-AU5-c-Fos (c-Fos-wt); and pCEFL-AUS-c-Fos-mut (c-Fos-m), which contains the following mutations: T232A, T325A, T331A, and S374A; gift from S. Gutkind, National Institutes of Health, MD; see Fig. 8 B Monje et al., 2003).

**Cell culture**

NIH-3T3, COS-7, HEK293, U2OS, and Hela cells were obtained from the American Type Culture Collection. Immo-null and littermate wild-type MEFs are described elsewhere (Sullivan et al., 1999). Cells maintained in DME supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mmol/L-glutamine (Invitrogen) and 10% FBS (or 10% NBS for NIH-3T3 cells) were incubated at 37°C in a 5% CO2/95% O2 atmosphere. Cultures were serum starved for 24 h and then stimulated with either 10% FBS, 10% NBS, PDGF-BB (20 ng/ml; Sigma-Aldrich), or EGF (100 ng/ml; Sigma-Aldrich). For ERK1/2 inhibition, PD98059 (20 μM; Tocris) or U0126 (10 μM; Promega) were added before serum stimulation. MG132 and cycloheximide were from Sigma-Aldrich. When indicated, cells were treated as schematized in Fig. 2 A.

**In vitro pull-down assays**

GST proteins were purified using glutathione-Sepharose 4B (GE Healthcare) and eluted with 50 mM Tris-Cl (pH 8.0). For the experiments of Fig. 5, GST proteins and cell lysates from NIH-3T3 cells were incubated in 20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF supplemented with complete protease inhibitor cocktail (Roche). After 16 h of incubation at 4°C, glutathione-Sepharose 4B was added to a final concentration of 10% and agitated at 4°C for 45 min. The beads were collected by centrifugation and washed three times with 20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF. For the experiments of Fig. 8 C, whole cell lysates from HEK293 cells were incubated with GST-lamin A bound to glutathione-Sepharose 4B beads. After 4 h of incubation at 4°C, the beads were collected by centrifugation and washed twice with 1% NP-40/PBS. In all cases, pellets were air-dried, resuspended in 2x Laemmli buffer, boiled for 5 min, and separated onto 12% SDS–polyacrylamide gels (SDS-PAGE).

**Subcellular fractionation, immunoprecipitation, and immunoblot experiments**

Immunoprecipitation and Western blot analysis were performed as previously described (Ivorra et al., 2006; Casar et al., 2007). Subcellular fractionation was performed as described by Schreiber et al. (1989) with minor modifications (Ivorra et al., 2006). In brief, cells were washed with PBS and scraped into TEN buffer (150 mM NaCl, 1 mM EDTA, and 40 mM TrisCl at pH 7.4). Cells were collected by brief centrifugation in microfuge tubes and resuspended in 10 mM Hepes (pH 7.9), 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 0.5 mM PMSF. After 15 min on ice, Nonidet NP-40 (Fluka) was added to a final concentration of 1%, and tubes were vortexed. Lysates were centrifuged at 4°C in a microfuge set at maximum speed to obtain in the soluble cytoplasmic fraction (supernatant) and the nuclear pellet, which was resuspended in ice-cold 20 mM Hepes (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF, and agitated at 4°C for 15 min. The nuclear lysate was centrifuged for 45 min at 4°C to obtain the SNF and the pellet containing the ERNF.

**In situ nuclear matrix isolation and indirect immunofluorescence analysis**

In situ nuclear matrix isolation was performed as described previously (Fey et al., 1984). In brief, cells grown on coverslips were washed in PBS and extracted twice in cytoskeleton buffer (CSK: 100 mM NaCl, 300 mM sucrose, 10 mM PIPES (pH 6.8), 3 mM MgCl2, 0.5% Triton X-100, and 1.2 M NaCl) for 10 min at 0°C. The resulting soluable fraction was removed. Extraction buffer (250 mM ammonium sulfate, 300 mM sucrose, 10 mM PIPES (pH 6.8), 3 mM MgCl2, 1.2 mM PMSF, and 0.5% Triton X-100) was added to the Triton X-100 insoluble structures for 10 min at 0°C and the cytoskeleton fraction was removed. DNase digestion was performed twice in digestion buffer (CSK buffer containing 100 μg/ml DNase I and 50 mM NaCl) followed by extraction in digestion buffer containing 0.25 M (NaCl). In situ–extracted and control cells were fixed in 4% formaldehyde/PBS and permeabilized with 0.5% Triton X-100. Samples were then incubated with species–appropriate FITC–conjugated secondary antibody. After washes and incubation with anti–lamin A/C (1:100; sc-7292) for 1 h at room temperature, specimens
were washed and incubated with an anti-mouse secondary antibody conjugated to Alexa 633 (1-300).

**Phosphatase treatment**

NIH-3T3 cells were rapidly washed with cold PBS and collected for subcellular fractionation as described above. When indicated, fractionation was performed in the absence of phosphatase inhibitors, DTT, and PMSE. Aliquots of the SNF were incubated in the absence or presence of 1 U of alkaline phosphatase (Roche) for 1 h at 37°C. Reactions were stopped by adding SDS sample buffer and processed for immunoblotting.

**EMSA**

Double-stranded oligonucleotides containing the AP-1 (5’-CGCTTGA-TGGATCGAC-3’; AP-1 site underlined) and the Sp1 (5’-ATGCTGAGCCGC-GGGGGACGC-3’; Sp1 site underlined) consensus sites were labeled with γ[32P]ATP using polynucleotide kinase (New England Biolabs, Inc.) and purified on a Sephadex G-50 column. EMSA was performed using the SNF of NIH-3T3 cells (5 μg total protein) and wild-type and lamin A/C-null mice MEFs (15 μg total protein) as previously described (Ivorra et al., 2006).

**Confocal microscopy**

Images were acquired on a laser confocal microscope (TCS/SP2; Leica) with a 63x oil immersion objective (NA 1.4). An argon laser line of 458 nm was used to excite Alexa 488, Texas red, and Alexa 633 (Molecular Probes, Inc.) after anti-lamin B antibody incubation. Finally, secondary antibodies conjugated to Alexa 633 were used (1:300). Image quantification was done using MetaMorph software (MDS Analytical Technologies).

**FRET**

NIH-3T3 cells were cotransfected with pECFP-lamin A + pEYFP-C-Fos or pECFP-Lamin A + EYFP as a negative control (1 μg each plasmid) using Lipofectamine (Invitrogen). Cotransfection of pECFP-YFP + pDNA3 (0.5 μg each) was used as positive control to calibrate the system. Images were acquired on a confocal microscope (TCS/SP2; Leica) with a 63x oil immersion objective (NA 1.4). An argon laser line of 458 nm was used to excite CFP (PMT window 465–505 nm) and a 514-nm line (20% laser intensity for acquisition and 65% for photobleaching) to excite YFP (PMT window: 525–600 nm). Studies were performed in 4% paraformaldehyde-fixed cells using the acceptor-phothobleaching method (Kennwirth, 2001) as previously described (Ivorra et al., 2006), in which FRET is calculated as the relative increase in donor fluorescence as a result of the reduction or elimination of energy transfer when the acceptor is photobleached. Specifically, we used the following equation: \[ \text{FRET} = \frac{C_{\text{before}} - C_{\text{after}}}{C_{\text{after}}} \times 100, \] where \( C_{\text{before}} \) and \( C_{\text{after}} \) are the total fluorescence intensity of the CFP channel before and after photobleaching, respectively. For negative values, this parameter was considered 0.

**Luciferase gene reporter assays**

Wild-type and lamin A/C-null MEFS were transiently transfected with 5 μg of AP-1-dependent cell 73-luciferase reporter plasmid and pGlu4Renilla luciferase using the calcium phosphate method. U2OS were transfected with 5 μg of cell/3-luciferase plus either a plasmid encoding for a miRNA-control/GFP or miRNA-LMNA/GFP (BLOCKit; Invitrogen). After 48 h in 10% FBS, cells were harvested and luciferase activity was measured following the manufacturer’s instructions (dual luciferase reporter assay system; Promega). Luciferase activity and GFP expression were measured in a luminometer (Victor). miRNA-transfected cells were also fixed in 4% PFA and studied by immunofluorescence confocal microscopy, or lysed for Western blot analysis.

**Statistical analysis**

Results are reported as mean ± SE. In experiments with two groups, differences were evaluated using a two-tailed, unpaired Student’s t test. One-way ANOVA and Bonferroni’s post hoc test was used for experiments involving more than two groups.

---

We thank M.J. Andrés-Manzano for help with the preparation of figures, and D. Barretton for critical reading of the manuscript. We are also grateful to colleagues who generously provided reagents (S. Gutiérrez: c-fos-wt, c-fos-m; T. Ozaki: pGEXlamin A; J. López-Giménez: pECFYP-YPF; R. Forsin, and C.I. Stewart: wt and lamin A-null MEFs). V. Andrés’s laboratory is supported by grants SAF2004-03057 and SAF2007-6211 (Spanish Ministry of Science and Innovation―MICINN) and European Regional Development Fund (FEDER), and RD06/0014/0021 (Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares, Instituto de Salud Carlos III―ISICII).

C. Crespo’s laboratory is supported by grants BFU2005-00777 and GEN2003-20239-C06-03 (MICINN), the EU Sixth Framework Program under the GROWTHSTOP (ISHC CT2006-037731) and SWAP (IST2004-027265) projects, and RD6/0020/0105 (Red Temática de Investigación Cooperativa en Oncología―ISICII). M. González received salary support from ISCIII and a research grant from Generalitat Valenciana (GVFRE/2008/163).

Submitted: 9 May 2008
Accepted: 20 October 2008

---

**References**

Abate, C., D.R. Marshak, and T. Curran. 1991. Fos is phosphorylated by p34cdc2, cAMP-dependent protein kinase and protein kinase C at multiple sites clustered within regulatory regions. Oncogene. 6:2179–2185.

Abe, M.K., W.L. Kuo, M.B. Hershenson, and M.R. Rosner. 1999. Extracellular signal-regulated kinase (ERK) 7, a novel ERK with a C-terminal domain that regulates its activity, cellular localization, and cell growth. Mol. Cell. Biol. 19:1301–1312.

Bossis, G., P. Ferrara, C. Avaciquva, I. Jarrel-Encontre, and M. Pechaczky. 2003. c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitylination in vivo. Mol. Cell. Biol. 23:7425–7436.

Broers, J.L., F.C. Ramaekers, G. Bonne, R.B. You, and C.J. Hutchison. 2006. Nuclear lamins: lamina stability and their role in premature ageing. Physiol. Rev. 86:967–1008.

Bueno, O.F., L.J. De Windt, K.M. Tymiz, S.A. Witt, T.R. Kimball, R. Klevitsky, T.E. Hewett, S.P. Jones, D.J. Lefer, C.F. Peng, et al. 2000. The MEK-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:6341–6350.

Callaway, K., M.A. Rainey, and K.N. Dalby. 2005. Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJ1 domains. Biochim. Biophys. Acta. 1754:316–323.

Casar, B., V. Sanz-Moreno, M.N. Yazicioglu, J. Rodriguez, M.T. Berciano, M. Lafarga, M.H. Cobb, and P. Crespo. 2007. Mxi2 promotes stimulus-independent ERK nuclear translocation. EMBO J. 26:635–646.

Chen, R.H., C. Abate, and J. Blenis. 1993. Phosphorylation of the c-Fos transcription-repression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA. 90:10952–10956.

Chen, R.H., P.C. Joo, T. Curran, and J. Blenis. 1996. Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Oncogene. 12:1493–1502.

Crespo, P., N. Xu, W.F. Simonds, and J.S. Gutkind. 1994. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature. 369:418–420.

Csoka, A.B., S.B. English, C.P. Simkevich, D.G. Ginzinger, A.J. Butte, G.P. Schatten, G.F. Rothman, and J.M. Sedivy. 2004. Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell. 3:235–243.

Deng, T., and M. Karin. 1994. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature. 371:171–175.

Dimitri, C.A., W. Dowdle, J.P. MacKeigan, J. Blenis, and L.O. Murphy. 2005. Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr. Biol. 15:1319–1324.

Dreuilhet, C., M. Harper, J. Tillit, M. Kress, and M. Ernoult-Lange. 2008. Mislocalization of human transcription factor MOK2 in the presence of pathogenic mutations of lamin A/C. J. Biol. Cell. 100:51–61.

Eferli, R., and E.F. Wagner. 2003. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer. 3:859–868.

Favreau, C., D. Huguet, J.C. Courvalin, and B. Buendia. 2004. Expression of a mutant lamin A that causes Emery-Dreifuss muscular dystrophy inhibits in vivo differentiation of C2C12 myoblasts. Mol. Cell. Biol. 24:1481–1492.

Favreau, C., E. Delbarre, J.C. Courvalin, and B. Buendia. 2008. Differentiation of C2C12 myoblasts expressing lamin A mutated at a site responsible for Emery-Dreifuss muscular dystrophy is improved by inhibition of the MEK-ERK pathway and stimulation of the PI3-kinase pathway. Exp. Cell Res. 314:1392–1405.

---

**AP-1 REGULATION BY c-FOS-ERK1/2-LAMIN A/C INTERACTIONS**

González et al. 665
Fey, E.G., K.M. Wan, and S. Penman. 1984. Epithelial cytoskeletal framework and nuclear matrix-intermediate filament scaffold: three-dimensional organization and protein composition. J. Cell Biol. 98:1973–1984.

Gruenbaum, Y., A. Margalit, R.D. Goldman, D.K. Shumaker, and K.L. Wilson. 2005. The lamina nucleai comes of age. Nat. Rev. Mol. Cell Biol. 6:21–31.

Heessen, S., and M. Fornerod. 2007. The inner nuclear envelope as a transcription factor resting place. EMBO Rep. 8:914–919.

Hill, C.S., and R. Treisman. 1995. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 80:199–211.

Hubner, S.J., E.A. Eam, A. Hubner, and D.A. Jans. 2006. Laminopathy-inducing lamin A mutants can induce redistribution of lamin binding proteins into nuclear aggregates. Exp. Cell Res. 312:171–183.

Hunter, T., and M. Karin. 1992. The regulation of transcription by phosphorylation. Cell. 70:375–387.

Ishibe, S., D. Joly, Z.N. Liu, and L.G. Cantley. 2004. Fuxilin serves as an ERK-regulated scaffold for coordinating FAK and rac activation in epithelial morphogenesis. Mol. Cell. 16:257–267.

Ito, Y., D. Inoue, S. Kido, and T. Matsumoto. 2005. c-Fos degradation by the ubiquitin-proteasome proteolytic pathway in osteoclast progenitors. Bone. 37:842–849.

Ivorra, C., M. Kubicek, J.M. Gonzalez, S.M. Sanz-Gonzalez, A. Alvarez-Borbonos, J.E. O’Connor, B. Burke, and V. Andres. 2006. A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. Genes Dev. 20:307–320.

Kahan, C., K. Seuwen, S. Meloche, and J. Pouyssegur. 1992. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylcyclase inhibition. J. Biol. Chem. 267:13369–13375.

Kenworthy, A.K. 2001. Imaging protein-protein interactions using fluorescent resonance energy transfer microscopy. Methods. 24:289–296.

Kerr, L.D., J.T. Holt, and L.M. Matrisian. 1988. Growth factors regulate transin expression by human fibroblasts. J. Biol. Chem. 263:7030–7036.

Kruijer, W., J.A. Cooper, T. Hunter, and I.M. Verma. 1984. Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. EMBO J. 3:803–814.

Lloyd, D.J., R.C. Trombath, and S. Shackleton. 2002. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum. Mol. Genet. 11:769–777.

Ly, D.H., D.J. Lockhart, R.A. Lerner, and P.G. Schultz. 2000. Mitotic misregulation and human aging. Science. 287:2486–2492.

Mariappan, I., and V.K. Parmaik. 2005. Sequestration of pRb by cyclin D3 causes synergistic activation of p44/p42 MAPK (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol. Endocrinol. 6:845–854.

Milanini-Mongiat, J., J. Pouyssegur, and G. Pages. 2002. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277:20631–20639.

Monje, P., M.J. Marinissen, and J.S. Gutkind. 2003. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol. Cell. Biol. 23:7030–7043.

Morrison, D.K., and R.J. Davis. 2003. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19:91–118.

Murphy, L.O., S. Smith, R.H. Chen, D.C. Fingar, and J. Blenis. 2002. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4:556–564.

Nicol, R.L., N. Frey, G. Pearson, M. Cobb, J. Richardson, and E.N. Olson. 2001. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiomyopathy. EMBO J. 20:2757–2767.

Oku, Y., D. Inoue, S. Kido, and T. Matsumoto. 2005. c-Fos degradation by the ubiquitin-proteasome proteolytic pathway in osteoclast progenitors. Bone. 37:842–849.

Piechaczek, M., and J.M. Blanchard. 1994. c-fos proto-oncogene regulation and function. Crit. Rev. Oncol. Hematol. 17:93–131.

Pullikuth, A., E. McKinnon, H.J. Schaefter, and A.D. Catling. 2005. The MEK1 scaffolding protein MP1 regulates cell spreading by integrating PAK1 and Rho signals. Mol. Cell. Biol. 25:5119–5133.

Robinson, F.L., A.W. Whitehurst, M. Raman, and M.H. Cobb. 2002. Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1. J. Biol. Chem. 277:14844–14852.

Robinson, M.J., S.A. Stippes, E. Goldsmith, M.A. White, and M.H. Cobb. 1998. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr. Biol. 8:1141–1150.

Sanz-Moreno, V., B. Casar, and P. Crespo. 2003. p38alpha isoform Msix2 binds to extracellular signal-regulated kinase 1 and 2 and mitogen-activated protein kinase and regulates its nuclear activity by sustaining its phosphorylation levels. Mol. Cell. Biol. 23:3079–3090.

Shapiro, P.S., E. Vaisberg, A.J. Hunt, N.S. Tolsinski, A.M. Whalen, J.R. McIntosh, and N.G. Ablin. 1998. Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen. J. Cell Biol. 142:1533–1545.

Sharrocks, A.D. 2001. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2:827–837.

Shaulian, E., and M. Karin. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4:E131–E136.

Sullivan, T., D. Escalante-Alcalde, H. Hhatt, M. Anver, N. Bhat, K. Nagashima, C.L. Stewart, and B. Burke. 1999. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J. Cell Biol. 147:913–920.

Taniura, H., C. Glass, and L. Gerace. 1995. A chromatin binding site in the tail domain of nuclear lamins that interacts with core histones. J. Cell Biol. 131:33–44.

Tanos, T., M.J. Marinissen, F.C. Leskow, D. Hochbaum, H. Martinetto, J.S. Gutkind, and O.A. Coso. 2005. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J. Biol. Chem. 280:18842–18852.

Torii, S., M. Kusakabe, T. Yamamoto, M. Maekawa, and E. Nishida. 2000. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2:110–116.

Teis, D., W. Wunderlich, and L.A. Huber. 2002. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev. Cell. 3:803–814.

Vlcek, S., and R. Foisner. 2007. A-type lamin networks in light of laminopathic diseases. Biochim. Biophys. Acta. 1773:661–674.

Whitehurst, A.W., F.L. Robinson, M.S. Moore, and M.H. Cobb. 2004. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J. Biol. Chem. 279:12840–12847.

Worman, H.J., and G. Bonne. 2007. “Laminopathies”: a wide spectrum of human diseases. Exp. Cell Res. 313:2121–2133.